These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10488328)

  • 41. "3+7" therapy for the treatment of acute myeloid leukemia. PRO.
    Schiffer CA
    Clin Adv Hematol Oncol; 2005 Feb; 3(2):127-9. PubMed ID: 16166981
    [No Abstract]   [Full Text] [Related]  

  • 42. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
    Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
    Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategies in the treatment of acute myeloid leukemia.
    Lowenberg B
    Haematologica; 2004 Sep; 89(9):1029-32. PubMed ID: 15377460
    [No Abstract]   [Full Text] [Related]  

  • 47. Postremission therapy in older adults with acute myeloid leukemia: an opportunity for new drug development.
    Schiffer CA
    Leukemia; 2002 Apr; 16(4):745-7. PubMed ID: 11960360
    [No Abstract]   [Full Text] [Related]  

  • 48. Multivariate analysis of factors associated with prognosis for adult acute leukemia.
    Murakami H; Hiraoka A; Nakura E; Hamajima N; Yamada K; Kimura K
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1607-16. PubMed ID: 3073620
    [No Abstract]   [Full Text] [Related]  

  • 49. Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group.
    Reiffers J; Maraninchi D; Rigal-Huguet F; Michallet M; Marit G; Stoppa AM; Attal M; Hollard D
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):90-2. PubMed ID: 1780761
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute myeloid leukemia in the elderly: 'per aspera ad astra'?
    Latagliata R; Petti MC; Mandelli F
    Leuk Res; 1999 Jul; 23(7):603-13. PubMed ID: 10400181
    [No Abstract]   [Full Text] [Related]  

  • 51. [How to improve results of chemotherapy of acute myeloid leukemia in adults: research of the cooperative group for studying acute myeloid leukemia in West Germany].
    Biukhner T; Khiddeman V; Mashmeĭer G; Liudvig V; Lëffler Kh; Novrusian M; Aul S; Kheĭneke A
    Gematol Transfuziol; 1991 Sep; 36(9):38-40. PubMed ID: 1769512
    [No Abstract]   [Full Text] [Related]  

  • 52. Acute myeloid leukaemia in the elderly: biology and treatment.
    Johnson PR; Liu Yin JA
    Br J Haematol; 1993 Jan; 83(1):1-6. PubMed ID: 7679585
    [No Abstract]   [Full Text] [Related]  

  • 53. The challenge of acute myeloid leukemia in older patients.
    Sekeres MA; Stone RM
    Curr Opin Oncol; 2002 Jan; 14(1):24-30. PubMed ID: 11790976
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Home treatment for intensive hematological therapies: who will benefit?
    Schouten HC
    Ann Oncol; 2006 May; 17(5):731-2. PubMed ID: 16638950
    [No Abstract]   [Full Text] [Related]  

  • 55. Improved outcome with intensive chemotherapy in paediatric acute myeloid leukaemia.
    Tan RM; Quah TC; Aung LL; Shen L; Kham SK; Kirk RC; Yeoh AE
    Ann Acad Med Singap; 2004 Sep; 33(5 Suppl):S39-41. PubMed ID: 15651200
    [No Abstract]   [Full Text] [Related]  

  • 56. Acute myeloid leukemia-type chemotherapy for myelodysplasia.
    Anderlini P; Pierce S; Kantarjian H; Estey E
    J Clin Oncol; 1996 Apr; 14(4):1404-5. PubMed ID: 8648402
    [No Abstract]   [Full Text] [Related]  

  • 57. Development of squamous cell carcinoma of the skin during induction chemotherapy for acute myeloid leukemia.
    Kottaridis PD; Goldstone AH
    Leuk Lymphoma; 2002 Feb; 43(2):459-60. PubMed ID: 11999590
    [No Abstract]   [Full Text] [Related]  

  • 58. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia.
    Manoharan A
    Br J Haematol; 2002 Aug; 118(2):683. PubMed ID: 12139766
    [No Abstract]   [Full Text] [Related]  

  • 59. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?
    Larson RA
    Leukemia; 2003 Mar; 17(3):488-91. PubMed ID: 12646935
    [No Abstract]   [Full Text] [Related]  

  • 60. Commentary: dose intensive chemotherapy in acute myeloid leukemia.
    Feldman EJ
    Leuk Res; 2001 Mar; 25(3):217-9. PubMed ID: 11226517
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.